Company Overview of VaxInnate, Inc.
VaxInnate, Inc., a biotechnology company, engages in the development and production of vaccines for pandemic and seasonal influenza diseases. Its products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company's products are used in the treatment of various diseases, including bacterial, viral, and parasitic infections. VaxInnate, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
3 Cedar Brook Drive
Cranbury, NJ 08512
Founded in 2002
Key Executives for VaxInnate, Inc.
Vice President of Business Development
Compensation as of Fiscal Year 2014.
VaxInnate, Inc. Key Developments
VaxInnate Begins Phase I Clinical Trial to Evaluate Quadrivalent Vaccine for Prevention of Seasonal Flu
Mar 19 14
VaxInnate Corporation announced that enrollment has commenced in a Phase 1 clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza. The VAX2012Q clinical trial is being funded in whole with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS), under Contract No. HHSO100201100011C. The trial, which is taking place at four sites in the United States, will evaluate the safety and immunogenicity of VAX2012Q. VAX2012Q is a dose escalation study. Up to 320 healthy adults aged 18-40 will receive VAX2012Q by intramuscular injection. The subjects will be evaluated in the clinic 21 days and six months post-vaccination, and followed for one year. The study is expected to yield data that will enable VaxInnate to select the appropriate dose of VAX2012Q for further development. Results are anticipated by the end of 2014. VaxInnate's technology platform is based on proprietary Toll-like Receptor (TLR) technology, which potentiates the immune response. The TLR technology genetically fuses vaccine antigens to the bacterial protein flagellin, and this sequentially triggers the innate and adaptive immune systems. Using this technology, vaccines can be produced using low-cost, highly-scalable, recombinant DNA techniques, thus avoiding many of the challenges of conventional vaccine production. This technology has the potential for production of significantly greater quantities of vaccine in extremely rapid timeframes, with very low infrastructure costs.
VaxInnate Corporation Presents at World Vaccine Congress Washington 2013, Apr-16-2013 through Apr-18-2013
Mar 26 13
VaxInnate Corporation Presents at World Vaccine Congress Washington 2013, Apr-16-2013 through Apr-18-2013. Venue: Gaylord National Hotel and Convention Center, Washington, District Of Columbia, United States. Presentation Date & Speakers: Apr-17-2013, Wayne Pisano, President & CEO.
VaxInnate, Inc. Presents at World Vaccine Congress Washington 2013, Apr-17-2013 04:40 PM
Mar 26 13
VaxInnate, Inc. Presents at World Vaccine Congress Washington 2013, Apr-17-2013 04:40 PM. Venue: Gaylord National Hotel and Convention Center, Washington, District Of Columbia, United States. Speakers: Wayne F. Pisano, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|